Literature DB >> 27488683

Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.

Ilya Lipkovich1, Alex Dmitrienko2, Ralph B3.   

Abstract

It is well known that both the direction and magnitude of the treatment effect in clinical trials are often affected by baseline patient characteristics (generally referred to as biomarkers). Characterization of treatment effect heterogeneity plays a central role in the field of personalized medicine and facilitates the development of tailored therapies. This tutorial focuses on a general class of problems arising in data-driven subgroup analysis, namely, identification of biomarkers with strong predictive properties and patient subgroups with desirable characteristics such as improved benefit and/or safety. Limitations of ad-hoc approaches to biomarker exploration and subgroup identification in clinical trials are discussed, and the ad-hoc approaches are contrasted with principled approaches to exploratory subgroup analysis based on recent advances in machine learning and data mining. A general framework for evaluating predictive biomarkers and identification of associated subgroups is introduced. The tutorial provides a review of a broad class of statistical methods used in subgroup discovery, including global outcome modeling methods, global treatment effect modeling methods, optimal treatment regimes, and local modeling methods. Commonly used subgroup identification methods are illustrated using two case studies based on clinical trials with binary and survival endpoints.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  biomarker analysis; clinical trials; data mining; exploratory subgroup analysis; multiplicity control

Mesh:

Substances:

Year:  2016        PMID: 27488683     DOI: 10.1002/sim.7064

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  43 in total

1.  Random forests of interaction trees for estimating individualized treatment effects in randomized trials.

Authors:  Xiaogang Su; Annette T Peña; Lei Liu; Richard A Levine
Journal:  Stat Med       Date:  2018-04-29       Impact factor: 2.373

Review 2.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

3.  Subgroup identification in clinical trials: an overview of available methods and their implementations with R.

Authors:  Zhongheng Zhang; Heidi Seibold; Mario V Vettore; Woo-Jung Song; Vieille François
Journal:  Ann Transl Med       Date:  2018-04

4.  Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.

Authors:  Stefan Schandelmaier; Matthias Briel; Ravi Varadhan; Christopher H Schmid; Niveditha Devasenapathy; Rodney A Hayward; Joel Gagnier; Michael Borenstein; Geert J M G van der Heijden; Issa J Dahabreh; Xin Sun; Willi Sauerbrei; Michael Walsh; John P A Ioannidis; Lehana Thabane; Gordon H Guyatt
Journal:  CMAJ       Date:  2020-08-10       Impact factor: 8.262

5.  Look before you leap: systematic evaluation of tree-based statistical methods in subgroup identification.

Authors:  Yang Liu; Xiwen Ma; Donghui Zhang; Lijiang Geng; Xiaojing Wang; Wei Zheng; Ming-Hui Chen
Journal:  J Biopharm Stat       Date:  2019-03-12       Impact factor: 1.051

6.  Q-Finder: An Algorithm for Credible Subgroup Discovery in Clinical Data Analysis - An Application to the International Diabetes Management Practice Study.

Authors:  Cyril Esnault; May-Line Gadonna; Maxence Queyrel; Alexandre Templier; Jean-Daniel Zucker
Journal:  Front Artif Intell       Date:  2020-12-17

7.  PSICA: Decision trees for probabilistic subgroup identification with categorical treatments.

Authors:  Oleg Sysoev; Krzysztof Bartoszek; Eva-Charlotte Ekström; Katarina Ekholm Selling
Journal:  Stat Med       Date:  2019-06-27       Impact factor: 2.373

8.  Auxiliary variable-enriched biomarker-stratified design.

Authors:  Ting Wang; Xiaofei Wang; Haibo Zhou; Jianwen Cai; Stephen L George
Journal:  Stat Med       Date:  2018-09-16       Impact factor: 2.373

9.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

10.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.

Authors:  David M Kent; Jessica K Paulus; David van Klaveren; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.